“We saw that with each additional enrichment feature the odds of finding a germline mutation would double,” says Alexis Rompré-Brodeur, MD.
Alexis Rompré-Brodeur, MD, a urologic oncologist at McGill University discusses results of the study, “Germline testing in renal cell carcinoma: can enrichment features help predict germline alterations?” which he presented at the 2022 AUA Annual Meeting (PD18-10).
Vobramitamab duocarmazine continues to show promise in mCRPC
May 10th 2024Updated data from the phase 2 TAMARCK study continued to show safety and preliminary efficacy with the B7-H3–targeting antibody-drug conjugate vobramitamab duocarmazine in patients with metastatic castration-resistant prostate cancer.